Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.64 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in lactotrophs | 0.75 |
| chemistry Open Targets | compounds already reach it: sumanirole, fluphenazine hydrochloride, ergoloid mesylates +108 | 1.00 |
| trials ClinicalTrials.gov | 8 Parkinson's trials, 3 stopped | 0.70 |
| literature PubMed | 209 Parkinson's papers of 3,229 | 0.30 |
| pathways Reactome | 1 pathway; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 11446
Earlier readings: 2026-10-26 0.49; 2026-10-25 0.49; 2026-10-24 0.49; 2026-10-23 0.49.
Sealed predictions
- DRD2 in dopamine neurons, braak-0.46 (p 0.214) → +0.03 (p 0.946)receipt 0531
- DRD2 in dopamine neurons, braak-0.07 (p 0.640) → -0.07 (p 0.645)receipt 0039
- DRD2 in dopamine neurons, resilience-0.16 (p 0.574) → +0.27 (p 0.314)receipt 0040
Swarm cases
receipt 0531: DRD2 in dopamine neurons, braak
- power
- full sample -0.16 (p 0.515, n 18), 95% CI -0.59 to +0.33. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.19 (p 0.450, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.30 (p 0.228, n 18). could be the mix.
- skeptic
- leave-one-out range -0.30 to -0.06, sign flips 0; without severely affected donors -0.16 (p 0.515, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DRD2 in dopamine neurons.
case closed: nothing better to follow up.
receipt 0040: DRD2 in dopamine neurons, resilience
- power
- full sample +0.09 (p 0.659, n 55), 95% CI -0.18 to +0.34. the interval is wide: not enough donors to tell.
- confounder
- adjusted for age, sex and PMI: +0.10 (p 0.614, n 55). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.12 (p 0.542); controlling for it: +0.10 (p 0.628, n 55). could be the mix.
- skeptic
- leave-one-out range +0.00 to +0.19, sign flips 1; without severely affected donors +0.06 (p 0.767, n 46). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "differs in resilient donors (Lewy pathology, no parkinsonism)" for DRD2 in dopamine neurons.
case closed: nothing better to follow up.
receipt 0039: DRD2 in dopamine neurons, braak
- power
- full sample -0.08 (p 0.480, n 84), 95% CI -0.29 to +0.14. the interval sits on zero: probably nothing there.
- confounder
- adjusted for age, sex and PMI: -0.09 (p 0.398, n 84). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis -0.72 (p 1.8e-14); controlling for it: -0.07 (p 0.519, n 84). could be the mix.
- skeptic
- leave-one-out range -0.11 to -0.05, sign flips 0; without severely affected donors -0.03 (p 0.770, n 75). fragile.
- cell type
- strongest in oligodendrocytes: -0.30 (p 0.0049, n 84) vs -0.08 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DRD2 in dopamine neurons.
follow-up confirmed in ventral tegmental area.
follow-up DRD2 · oligodendrocytes · braak: ventral tegmental area -0.34 p 0.0018 (needs p < 0.0071)
Receipts
loading the receipts